SequelSEC

Beta Bionics, Inc. BBNX

Surgical & Medical Instruments & Apparatus · CIK 0001674632 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$127.26M
Fiscal year ended 2026-09-30
Operating income
-$92.58M
Fiscal year ended 2026-09-30
Free cash flow
-$65.96M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$632.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$14.24Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue6.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio8.66x90th
Revenue YoY growth53.9%87th
SBC / revenue16.3%72th
Operating margin-71.5%29th
R&D / revenue34.7%71th
Net margin-73.0%30th
FCF margin-56.1%30th
CapEx / revenue5.3%67th
Gross margin55.4%37th

Beta Bionics, Inc. (BBNX) reported revenue of $127.26M and net income of -$83.12M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Beta Bionics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Beta Bionics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Revenue$127.26M
Cost of revenue$52.65M
Gross profit$74.61M
Operating income-$92.58M
Net income-$83.12M
Research & development$42.70M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$124.49M
General & administrative$37.66M
Selling & marketing$86.83M

Balance

Beta Bionics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$81.55M
Total assets$443.76M
Current assets$292.95M
Total liabilities$42.38M
Current liabilities$32.84M
Total equity incl. NCI$401.38M
Temporary (mezzanine) equityUnavailable
Inventory$22.97M
Accounts receivable$20.67M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$4.68M

Cash flow

Beta Bionics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow-$59.37M
Capital expenditures$6.59M
Investing cash flow-$64.65M
Financing cash flow$167.08M
Net change in cash$43.07M
Stock-based compensation$23.44M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Beta Bionics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flow-$65.96M
Gross margin58.6%
Operating margin-72.7%
FCF margin-51.8%
SBC / revenue18.4%
Current ratio8.92x
Revenue YoY growth43.7%
Net margin-65.3%
R&D / revenue33.6%
CapEx / revenue5.2%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BBNX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-27View SEC filing
10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-04-21View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-29View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.